Eurofins Scientific : H1 2022 Results Presentation

CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are

not the intended recipient of this document, you are hereby notified that the	use,
circulation, quoting,	or reproducing of	this	document is strictly prohibited and	may
be unlawful. Photo	images on this page	are	the copyrighted property of 123RF Limited.
D

H1 2022 Results Presentation

Eurofins posts record revenues of €3,412m and overall results well in excess of its

objectives in H1 2022 and increases its objectives for H2 and FY 2022

27 July 2022

www.eurofins.com

Disclaimer

This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific SE and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific's management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward looking statement or estimate.

Eurofins provides various alternative performance measures (APM) in its interim condensed consolidated financial statements. These measures exclude certain items because of the nature of these items and the impact they have on the analysis of the underlying business performance and trends. Management believes that presenting these APMs enhances investors' understanding of the Group's core operating results and future prospects, consistent with internal reporting used by management to measure and forecast the Group's performance. This information should be considered in addition to, but not in lieu of, the Group's operating results as reported in accordance with IFRS. These APMs are described in further detail in Notes 1.20 and 1.21 of the Group's consolidated financial statements as of and for the year ended 31 December 2021.

2

Agenda

1. Introduction and highlights

1. Financial review

1. Operational review

IV. Outlook

3

I. Introduction and highlights

4

Key operational highlights in H1 2022

• Record revenues of €3,412m, up 4.3% vs. H1 2021, driven by good growth of Eurofins' Core Business and continued demand for COVID-19 testing and reagents well in excess of its objectives previously increased on 21 April 2022
• The Core Business realized healthy organic growth (5.3% year-on-year) against record comparables and despite impacts from COVID-19 lockdowns in China as well as disruptions in Europe due to the war in Ukraine
• Once again COVID-19 testing has provided a hedge to compensate for disruptions:

• 1. While organic growth in the Core Business was approximately €35m below its mid-term objective of 6.5% which had been increased from 5% on 22 February 2022 just before the war in Ukraine started, Eurofins was able to overcompensate by generating in excess of €135m of revenues from COVID-19 related testing in Q2 2022 alone. This is ca. €100m above our objectives for COVID-19 testing in Q2 2022 and three times the €35m gap to the increased 6.5% Core Business growth objectives caused by current market disruptions
• The outlook for Eurofins Core Business growth is stronger for H2 2022 with easier comparables, price increases implemented recently and COVID-19 programs in BioPharma being gradually replaced by other studies

5